The Cigna Group (CI) earnings on July 30, 2026
Prior outlook: No statistical edge
Cigna's stock fell after news of slower growth in GLP-1 drug prescriptions, despite a slightly better profit outlook.
CI price around the earnings
287.66
Change: -3.2%
2026-07-30, 20:00 UTC
Start of the measured window
End of the measured window
279.16
285.58
292.01
298.43
297.27
July 30, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: No statistical edge
- Thesis published
- Results released
Analyst +15% upside, 100% beat rate, but Medicare subsidy termination and flat trend strength create headwinds.
Context analyzed before publication
- Trend
- Fluctuating trajectory into event, ending near neutral with mixed trend strength and macro headwinds.
Analysts
Evidence
- Analysts covering the stock
- 24
- Average price target
- 340.92
- Lowest price target
- 290
- Highest price target
- 400
- Upside to price target
- 15%
- Quarterly earnings growth
- 25%
- Revenue growth
- 4.6%
- Forward EPS
- 33.48
- Trailing EPS
- 23.24
- Analyst moves in the last 60 days
- 2
- Strong buy: 5
- Buy: 15
- Hold: 4
- Sell: 0
- Strong sell: 0
- Strong buy
- 5
- Buy
- 15
- Hold
- 4
- Sell
- 0
- Strong sell
- 0
- July 9, 2026 · Bernstein: Maintains rating (Outperform → Outperform)
- June 8, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (2)
- Bernstein Maintains Outperform on Cigna Group, Raises Price Target to $381 (opens in a new tab) — Benzinga
- Independent Pharmacies Accuse Prime Therapeutics of Price-Fixing Scheme With Express Scripts (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 296.5
- Average true range (ATR)
- 2.7%
- Distance to 52-week high
- -3.0%
- 14-day change (14d)
- -0.4%
- 30-day change (30d)
- +6.4%
- 30-day relative strength
- +7.9%
- SPY change (30d)
- -1.5%
- Nearest support
- 296.2
- Distance to nearest support
- 0.1%
- Nearest resistance
- 299.75
- Distance to nearest resistance
- 1.1%
- Volume accumulation ratio (14d / 46d)
- 1.29
- Major: 296.2 (0.1% away, 0.04 ATR, 37 touches)
- Mid: 294.77 (0.6% away, 0.21 ATR, 17 touches)
- Major: 293.34 (1.1% away, 0.39 ATR, 41 touches)
- Major: 299.75 (1.1% away, 0.4 ATR, 30 touches)
- Major: 301.13 (1.6% away, 0.57 ATR, 34 touches)
- Major: 302.62 (2.1% away, 0.75 ATR, 28 touches)
Trends
Evidence
- Average earnings surprise
- +2.0%
- April 30, 2026: actual EPS 7.79 vs estimate 7.61 (surprise +2.4%)
- February 5, 2026: actual EPS 8.08 vs estimate 7.88 (surprise +2.5%)
- October 30, 2025: actual EPS 7.83 vs estimate 7.64 (surprise +2.5%)
- July 31, 2025: actual EPS 7.2 vs estimate 7.15 (surprise +0.7%)
Expected move
- Implied move
- +7.1%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 4.1%
- 75th percentile move
- 6.1%
- 90th percentile move
- 10.6%
- Up / down moves
- 8 / 12
- Average up move
- +3.8%
- Average down move
- -5.5%
Monitoring and close
What The Cigna Group reported
- Status
- Finished
| Actual EPS | 7.78 |
|---|---|
| EPS estimate | 7.6 |
| EPS surprise | +2.4% |
| Revenue | $71,558 million |
| Revenue estimate | $70,339 million |
| Revenue surprise | +1.7% |
Cigna beats Q2 estimates on healthcare strength and raises 2026 outlook, but market remains pessimistic on rebate-free model transition.
Sources (17)
- CI Q2 Earnings Beat Estimates on Cigna Healthcare Strength (opens in a new tab) — Zacks
- Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions (opens in a new tab) — Benzinga
- Cigna Beat Earnings and Raised Guidance. Why the Stock Is Dropping. (opens in a new tab) — Barrons.com
- Cigna (CI) Reports Q2 Earnings: What Key Metrics Have to Say (opens in a new tab) — Zacks
- Cigna Exec Says Company Saw Some Deceleration In The Growth Rate Of Glp-1 Prescriptions (opens in a new tab) — Benzinga
- Cigna Earnings Beat Estimates but Guidance Boost Fails to Impress (opens in a new tab) — Barrons.com
- The Cigna Group (CI) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Cigna Group (NYSE:CI) Slightly Misses Q2 Estimates, Raises Full-Year Guidance (opens in a new tab) — ChartMill
- Cigna (CI) Q2 Earnings and Revenues Top Estimates (opens in a new tab) — Zacks
- Cigna (NYSE:CI) Surprises With Q2 CY2026 Sales (opens in a new tab) — StockStory
- Cigna beats Q2 estimates, lifts earnings guidance (opens in a new tab) — Investing.com
- Cigna Stock Slips as Earnings Beat Estimates but Guidance Boost Fails to Impress (opens in a new tab) — Barrons.com
- Cigna Group Lifts Outlook, Logs Higher Profit on Growth Across Businesses (opens in a new tab) — The Wall Street Journal
- Cigna Group FY2026 Adj EPS expected to be more than $30.45 vs $30.41 Est (opens in a new tab) — Benzinga
- Cigna Group reported adjusted earnings of $7.78 per share, beating the $7.60 estimate, and revenue of $71.558B, above the $70.339B forecast. — Benzinga
- Cigna Group Q2 Adj. EPS $7.78 Beats $7.60 Estimate, Sales $71.558B Beat $70.339B Estimate (opens in a new tab) — Benzinga
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, the company beat expectations on both earnings and revenue, and the stock is indicating a 3.9% drop pre-market, a move in line with its typical reaction of about 4%. The figures do not confirm the prior scenario because there was no directional scenario to check against.
How the stock reacted
- Consolidated
- -3.3%
- Max move
- -6.0%
No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.